Carboxylesterase 1 (CES1) genetic polymorphisms and oseltamivir activation

European Journal of Clinical Pharmacology

Volumn 69, Issue 3, 2013, Pages 733-734

  Zhu, Hao Jie ^a   Markowitz, John S ^a  

^a UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IRINOTECAN; OSELTAMIVIR;

AREA UNDER THE CURVE; CARBOXYLESTERASE 1 GENE; CARBOXYLESTERASE 1A1 GENE; CARBOXYLESTERASE 1A2 GENE; CARBOXYLESTERASE 1A3 GENE; DRUG METABOLISM; GENE; GENETIC POLYMORPHISM; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; LETTER; PHARMACODYNAMICS; PHARMACOGENETICS; PRIORITY JOURNAL; SMOKING;

ANTIVIRAL AGENTS; CARBOXYLIC ESTER HYDROLASES; FEMALE; HUMANS; MALE; OSELTAMIVIR;

EID: 84877146589     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-012-1350-2     Document Type: Letter

References (15)

1. Suzaki Y, Uemura N, Takada M, Ohyama T, Itohda A, Morimoto T, Imai H, Hamasaki H, Inano A, Hosokawa M, Tateishi M, Ohashi K (2012) The effect of carboxylesterase 1 (CES1) polymorphisms on the pharmacokinetics of oseltamivir in humans. Eur J Clin Pharmacol. doi: 10.1007/s00228-012-1315-5
2. Hosokawa M, Furihata T, Yaginuma Y, Yamamoto N, Watanabe N, Tsukada E, Ohhata Y, Kobayashi K, Satoh T, Chiba K (2008) Structural organization and characterization of the regulatory element of the human carboxylesterase (CES1A1 and CES1A2) genes. Drug Metabol Pharmacokinet 23(1):73-84
3. Fukami T, Nakajima M, Maruichi T, Takahashi S, Takamiya M, Aoki Y, McLeod HL, Yokoi T (2008) Structure and characterization of human carboxylesterase 1A1, 1A2, and 1A3 genes. Pharmacogenet Genomics 18(10):911-920. doi: 10.1097/FPC.0b013e32830b0c5e
4. Tanimoto K, Kaneyasu M, Shimokuni T, Hiyama K, Nishiyama M (2007) Human carboxylesterase 1A2 expressed from carboxylesterase 1A1 and 1A2 genes is a potent predictor of CPT-11 cytotoxicity in vitro. Pharmacogenet Genomics 17(1):1-10. doi: 10.1097/01.fpc.0000230110.18957.50
5. Sai K, Saito Y, Tatewaki N, Hosokawa M, Kaniwa N, Nishimaki-Mogami T, Naito M, Sawada J, Shirao K, Hamaguchi T, Yamamoto N, Kunitoh H, Tamura T, Yamada Y, Ohe Y, Yoshida T, Minami H, Ohtsu A, Matsumura Y, Saijo N, Okuda H (2010) Association of carboxylesterase 1A genotypes with irinotecan pharmacokinetics in Japanese cancer patients. Br J Clin Pharmacol 70(2):222-233. doi: 10.1111/j.1365-2125.2010.03695.x
6. Zhu HJ, Appel DI, Johnson JA, Chavin KD, Markowitz JS (2009) Role of carboxylesterase 1 and impact of natural genetic variants on the hydrolysis of trandolapril. Biochem Pharmacol 77(7):1266-1272. doi: 10.1016/j.bcp.2008.12.017
7. Zhu HJ, Markowitz JS (2009) Activation of the antiviral prodrug oseltamivir is impaired by two newly identified carboxylesterase 1 variants. Drug Metabol Dispos 37(2):264-267. doi: 10.1124/dmd.108.024943
8. Zhu HJ, Patrick KS, Yuan HJ, Wang JS, Donovan JL, DeVane CL, Malcolm R, Johnson JA, Youngblood GL, Sweet DH, Langaee TY, Markowitz JS (2008) Two CES1 gene mutations lead to dysfunctional carboxylesterase 1 activity in man: clinical significance and molecular basis. Am J Hum Genet 82(6):1241-1248. doi: 10.1016/j.ajhg.2008.04.015
9. Tarkiainen EK, Backman JT, Neuvonen M, Neuvonen PJ, Schwab M, Niemi M (2012) Carboxylesterase 1 polymorphism impairs oseltamivir bioactivation in humans. Clin Pharmacol Ther. doi: 10.1038/clpt.2012.13
10. Nemoda Z, Angyal N, Tarnok Z, Gadoros J, Sasvari-Szekely M (2009) Carboxylesterase 1 gene polymorphism and methylphenidate response in ADHD. Neuropharmacology 57(7-8):731-733. doi: 10.1016/j.neuropharm.2009.08.014
11. Bruxel EM, Salatino-Oliveira A, Genro JP, Zeni CP, Polanczyk GV, Chazan R, Rohde LA, Hutz MH (2012) Association of a carboxylesterase 1 polymorphism with appetite reduction in children and adolescents with attention-deficit/ hyperactivity disorder treated with methylphenidate. Pharmacogenomics J. doi: 10.1038/tpj.2012.25tpj201225
12. Shi D, Yang J, Yang D, LeCluyse EL, Black C, You L, Akhlaghi F, Yan B (2006) Anti-influenza prodrug oseltamivir is activated by carboxylesterase human carboxylesterase 1, and the activation is inhibited by antiplatelet agent clopidogrel. J Pharmacol Exp Ther 319(3):1477-1484
13. Geshi E, Kimura T, Yoshimura M, Suzuki H, Koba S, Sakai T, Saito T, Koga A, Muramatsu M, Katagiri T (2005) A single nucleotide polymorphism in the carboxylesterase gene is associated with the responsiveness to imidapril medication and the promoter activity. Hypertens Res 28(9):719-725
14. Patrick KS, Straughn AB, Minhinnett RR, Yeatts SD, Herrin AE, DeVane CL, Malcolm R, Janis GC, Markowitz JS (2007) Influence of ethanol and gender on methylphenidate pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 81(3):346-353. doi: 10.1038/sj.clpt.6100082
15. Yamada S, Richardson K, Tang M, Halaschek-Wiener J, Cook VJ, Fitzgerald JM, Elwood K, Marra F, Brooks-Wilson A (2010) Genetic variation in carboxylesterase genes and susceptibility to isoniazid-induced hepatotoxicity. Pharmacogenomics J 10(6):524-536. doi: 10.1038/tpj.2010.5